(NYSE:AI) Stephen Ehikian is taking over as CEO, succeeding Thomas Siebel, who revealed that he was diagnosed with an autoimmune disease.
Related Questions
How will the CEO transition affect C3 AI's strategic initiatives and execution timeline?
What revisions, if any, are expected for the company's revenue guidance and earnings forecasts following the decline?
How might this leadership change influence investor sentiment and short‑term price volatility relative to peers?